# Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

> **NCT01375777** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 411 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Ezetimibe
- **OTHER:** Placebo to Evolocumab

## Key facts

- **NCT ID:** NCT01375777
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-06
- **Primary completion:** 2012-03-02
- **Final completion:** 2012-03-02
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01375777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01375777, "Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01375777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*